Achilles Therapeutics plc (ACHL): Price and Financial Metrics


Achilles Therapeutics plc (ACHL): $1.75

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACHL Stock Price Chart Interactive Chart >

Price chart for ACHL

ACHL Price/Volume Stats

Current price $1.75 52-week high $5.65
Prev. close $1.75 52-week low $1.58
Day low $1.71 Volume 29,700
Day high $1.87 Avg. volume 64,438
50-day MA $2.03 Dividend yield N/A
200-day MA $2.57 Market Cap 68.52M


ACHL Latest News Stream


Event/Time News Detail
Loading, please wait...

ACHL Latest Social Stream


Loading social stream, please wait...

View Full ACHL Social Stream

Latest ACHL News From Around the Web

Below are the latest news stories about ACHILLES THERAPEUTICS PLC that investors may wish to consider to help them evaluate ACHL as an investment opportunity.

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that United States (US) patent 11,504,398 has been granted. The patent covers the treatment of pat

Yahoo | November 22, 2022

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | November 13, 2022

Chardan Capital Keeps Their Buy Rating on Achilles Therapeutics (ACHL)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics (ACHL - Research Report) today and set a price target of $20.00. The company's shares closed yesterday at $1.79.Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Solid Biosciences. According to TipRanks, Livshits has an average return of 24.8% and a 40.24% success rate on recommended stocks. Achilles Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.See the top stocks recommended by analysts >>The company has a one-year high of $6.88 and a one-year low of $1.72. Currently, Achilles Therapeutics has an average volume of 26.92K.

Christine Brown on TipRanks | November 9, 2022

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of $179.9 million supports all planned operations into Q2 2025 - LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced its financial results for the

Yahoo | November 8, 2022

What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | November 1, 2022

Read More 'ACHL' Stories Here

ACHL Price Returns

1-mo -9.79%
3-mo -40.07%
6-mo -30.28%
1-year -62.20%
3-year N/A
5-year N/A
YTD -65.07%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.808 seconds.